| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total operating expenses | 45,251 | 34,897 | 36,281 | |
| Loss from operations | -35,251 | -34,897 | -35,842 | |
| Interest income | 10,938 | 11,389 | 7,783 | |
| Total other income | 10,938 | 11,389 | 7,783 | |
| Net loss | -24,313 | -23,508 | -28,059 | |
| Unrealized gain on available-for-sale securities, net | 815 | 1,593 | 9,447 | |
| Comprehensive loss | -23,498 | -21,915 | -18,612 | |
| Earnings per share, basic, total | -0.39 | -0.38 | -0.51 | |
| Net loss per common share, diluted | -0.39 | -0.38 | -0.51 | |
| Weighted average number of shares outstanding, diluted | 62,023,685 | 61,791,721 | 54,628,670 | |
| Weighted-average shares of common stock outstanding, basic | 62,023,685 | 61,791,721 | 54,628,670 | |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)